

Cell & Gene Therapy Bioprocessing & Commercialization

October 5-7, 2016 • Boston Convention and Exhibition Center • Boston, MA

**THE MOST COMPLETE EVENT TO SUCCESSFULLY
BLUEPRINT CELL, GENE, AND IMMUNOTHERAPIES
FROM PROOF OF CONCEPT TO COMMERCIALIZATION**

New gene therapy development
& production track

Ensure successful process and
product development

Navigate the pathway to
commercialization

Meet the right partners to
grow your business

cellgeneevent.com



ENSURE SUCCESSFUL PROCESS AND PRODUCT DEVELOPMENT

Recent innovations in cell processing and technologies are now yielding clinical and commercial success. Hear the very latest applications of these disruptive technologies, platforms, and approaches to ensure successful development, characterization, scale up and transfer of these therapies and accelerate their path to approval.



NAVIGATE THE PATHWAY TO COMMERCIALIZATION

Gain insights from global thought-leading speakers on how overcome today's challenges with: fostering investment, partnerships and outsourcing opportunities; facility design and management; clinical trial design and development; strategies for clinical and commercial launch; fill-finish; reimbursement, pricing, adoption and much more.



MEET THE RIGHT PARTNERS TO GROW YOUR BUSINESS

Connect with 300+ thought-leaders and service providers who can offer the strategic, technical and financial support to ensure success cell-based product launch and efficacious patient outcomes.

HEAR FROM WORLD-RENOWNED VISIONARIES TO BUILD A SUCCESSFUL, SUSTAINABLE PRODUCTS

Featured Sessions



KEYNOTE ADDRESS:

Adult Mesenchymal Stem Cells: The New Medicine

Arnold I. Caplan, Ph.D., Professor and Director, Skeletal Research Center, The Department of Biology, Case Western Reserve University



Funding & Investment in the Cell & Gene Therapy Field

Brock Reeve, Mphil., Executive Director, Harvard Stem Cell Institute



Building a Sustainable Academic Engine for Feeding De-Risked Assets into the Biopharma Pipeline

David DiGiusto, Ph.D., Executive Director, Stem Cells and Cellular Therapeutics Operations; Founding Director, Stanford Laboratory for Cell and Gene Medicine; Senior Research Scientist, Division of Pediatric Stem Transplantation and Regenerative Medicine, Stanford Health Care/Stanford School of Medicine



AGENDA AT-A-GLANCE

WEDNESDAY, OCTOBER 5, 2016

Exposition Hall Hours: 4:30pm – 6:30pm

	Cell Therapy Bioprocessing	Tools & Technologies	NEW! Gene Therapy Development & Production	Commercialization
AM	Innovations in Cell Processing - Part 1 <i>Sponsored by Corning</i>		Overcoming Scientific and Development Challenges	Investment, Partnership and Co-Development Opportunities
	Technologies & Methodologies for Analytical Development		Emerging Research: Delivery Strategies and Genome Engineering Technologies	Adopting Commercialization Scale Technologies
	Lunch on Your Own			
PM	Innovations in Cell Processing - Part 2		Manufacturing Strategies and Solutions for Gene Therapies <i>Sponsored by Pall Life Sciences</i>	Designing, Building and Managing GMP Manufacturing Facilities
	Keynote Presentations			
	Grand Opening Reception in the Exposition Hall: "Celebration of Science" Co-Sponsored by GE Life Sciences and KNeCT365 and Lonza			

THURSDAY, OCTOBER 6, 2016

Exposition Hall Hours: 9:45am – 6:30pm

	Cell Therapy Bioprocessing	Tools & Technologies		Commercialization
AM	Progress of Bioprinting & Tissue Engineering Technologies in the Clinic			Raw Materials & Supply Chain – Improving Quality, Control & Logistics <i>Hosted by: CharterMedical</i>
	Ensuring Successful Scale Up and Technology Transfers	Tools & Technologies	Immuno-Oncology	Clinical Trial Design & Development
		Industrialization of Cell & Therapies		
	Technology Workshop Presentations (opportunities still available)			
	Networking Luncheon in the Exposition Hall			
	Cell Therapy Bioprocessing	Tools & Technologies	Immuno-Oncology	Commercialization
PM	Evolving Expectations & Considerations for Characterization & Comparability	Overcoming Bottlenecks and Designing Universal Development & Manufacturing Solutions		Strategies for Clinical & Commercial Launch
	STAT Panel Discussion			
	Party in the Park			

FRIDAY, OCTOBER 7, 2016

Exposition Hall Hours: 9:15am – 2:00pm

	Cell Therapy Bioprocessing	Tools & Technologies	Regulatory Considerations	Commercialization
AM	Keynote Presentation			
	Innovations in Process Technologies <i>Sponsored by Fresenius Kabi</i>	International Regulatory Perspectives		Reimbursement, Pricing & Adoption
		Analysis and Breakthrough Designations for Cell & Gene Therapies		
		Standards & Compliance		
	Technology Workshop Presentations (opportunities still available)			
	Networking Luncheon in the Poster & Exposition Hall			
PM	Innovations in Process Technologies (continued)		Drug Product and Fill-Finish Strategies for Cell Therapy Products	

	Cell Therapy Bioprocessing	Tools & Technologies	NEW! Gene Therapy Development & Production	Commercialization
7:30	<i>Registration and Coffee</i>			
8:25	Chairperson's Opening Remarks Richard Eglan, Ph.D., General Manager, Corning Life Sciences	Chairperson's Opening Remarks Anthony Davies, President, Dark Horse Consulting	Chairperson's Opening Remarks Nick Timmins, Ph.D., Vice President, Technology, Centre for Commercialization of Regenerative Medicine	
	Innovations in Cell Processing - Part 1 <i>Sponsored by</i> CORNING	Overcoming Scientific and Development Challenges	Investment, Partnership and Co-Development Opportunities	
8:30	Automating CAR-T Cell Manufacturing: Building a Solid Foundation Rod Rietze, MSc, Ph.D., Associate Director, Process Automation, Technical Research and Development, Novartis Cell and Gene Therapy Unit	Extended Range and Next Generation Chimeric Antigen Receptor T Cells NEW DATA Bruce Levine, Ph.D., Barbara and Edward Netter Professor in Cancer Gene Therapy, Pathology and Laboratory Medicine, University of Pennsylvania	FEATURED PRESENTATION: Funding & Investment in the Cell & Gene Therapy Field Brock Reeve, Mphil., Executive Director, Harvard Stem Cell Institute	
9:00	Manufacturing Platform Approaches for Lentiviral-Based Gene Therapies Mike Paglia, MSc., Senior Director, Technical Operations, Cellular Process Development and Manufacturing Operations, Pharmaceutical Sciences, bluebird bio, Inc.	MSCs on Steroids Jeffrey M. Karp, Ph.D., Associate Professor, Biomedical Engineering, Brigham and Women's Hospital	Spin-Out of a Company Through the Out-Licensing of Technology from an Academic Institution Ben Bergo, Chief Executive Officer, Nohla	
9:30	Next Generation Cell Expansion Technologies for Stem Cell Therapy Jennifer Weber, Senior Development Scientist, Life Sciences, Corning Incorporated	Stabilizing Lentivirus Vector Formulations for CAR-T Cell Therapy Application CASE STUDY NEW DATA Amitabha Deb, Ph.D., Associate Director, Senior Fellow, Cell and Gene Therapies, Novartis Pharmaceuticals	Manufacturing – A Key for a Successful and Profitable Product CASE STUDY Devyn Smith, Ph.D., Head of Strategy, Medicinal Sciences Division of Pfizer R&D, Pfizer Inc.	
10:00	<i>Networking Refreshment Break</i>			
	Technologies & Methodologies for Analytical Development	Emerging Research: Delivery Strategies and Genome Engineering Technologies	Adopting Commercialization Scale Technologies	
10:30	Discovery and Use of Cell Therapy Biomarkers NEW DATA David F. Stroncek, Ph.D., Chief, Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center	Genetic Engineering Red Blood Cells for Therapeutic Function CASE STUDY NEW DATA Robert J. Deans, Ph.D., Chief Scientific Officer, Rubius Therapeutics	Thinking Outside the Vial: Plug and Play Stem Cell Systems for Rapid Manufacturing Process Development NEW DATA Jon A. Rowley, Ph.D., Chief Executive and Technical Officer, RoosterBio Inc.	
11:00	Considerations for Cell Product Release Testing Alexey Bersenev, Ph.D., M.D., Lab Director, Advanced Cell Therapy Lab, Yale University, Yale-New Haven Hospital	Novel Approaches to Gene Editing and Gene Delivery NEW DATA Andrew M. Scharenberg, M.D., Professor of Pediatrics, Adjunct Immunology, University of Washington and Co-director, Program in Cell and Gene Therapy, Seattle Children's Research Institute	Process Development and Scale-up for the Production of Hematopoietic Stem Cells CASE STUDY Jason N. Carstens, Ph.D., Vice President, Manufacturing, Nohla Therapeutics, Inc.	
11:30	Particulates John McMannis, Ph.D., Executive Vice President, Manufacturing, Mesoblast	Development of Stem Cell Derived Extracellular Vesicles into a Non-Living Regenerative Therapeutic Drug Candidate NEW DATA Michelle R. Kreke, Ph.D., Senior Director of Product Development & Manufacturing, R&D and Manufacturing, Capricor, Inc.	The Evolution of a Manufacturing and Development Strategy as Autologous Gene Therapies Progress to Commercialization Mark D. Angelino, Ph.D., Senior Vice President, Pharmaceutical Sciences, bluebird bio	
	Technology Workshop			
12:00	Nutrient Requirements of Optimal T Cells Expansion Under Defined Conditions CASE STUDY NEW DATA Jessie H-T Ni, Ph.D., Chief Scientific Officer, Irvine Scientific			
12:45	<i>Lunch on Your Own</i>			

	Cell Therapy Bioprocessing	Tools & Technologies	NEW! Gene Therapy Development & Production	Commercialization
2:10	Chairperson's Remarks		Chairperson's Remarks	Chairperson's Remarks
	Innovations in Cell Processing - Part 2		Manufacturing Strategies and Solutions for Gene Therapies <i>Sponsored by</i>  Life Sciences	Designing, Building and Managing GMP Manufacturing Facilities
2:15	CAR T production in G-Rex: Less is More Juan Vera, M.D., Assistant Professor, Cell and Gene Therapy Center, Baylor College of Medicine	CASE STUDY	Achieving Large-Scale GMP Production of Adenovirus in the iCELLis 500 Fixed-Bed Bioreactor Hanna Lesch, Ph.D., Research & Development Director, FinVector Vision Therapies, Finland	Multiproduct Large Scale Cell and Gene Therapy Catapult Manufacturing Facility Stephen Ward, Ph.D., Chief Operating Officer, Cell Therapy Catapult
2:45	Approaches for Determining Technologies to Pursue for Cell Therapy Bioprocessing Brian Murphy, Ph.D., Director of Development, Celgene Cellular Therapeutics		Manufacturing Considerations, Benefits and Challenges Lance Weed, Vice President, US Operations, uniQure	Design, Build, & Commissioning of CDMO CF/GT Facilities in Asia Kim D. Raineri, BSc., MBA, Vice President of Operations, NIKON CeLL innovation Co., Ltd., Japan
3:25	Chairperson's Remarks Lee Buckler, President & CEO, RepliCel			
	Keynote Presentations			
3:30	Adult Mesenchymal Stem Cells: The New Medicine Arnold I. Caplan, Ph.D., Professor and Director, Skeletal Research Center, The Department of Biology, Case Western Reserve University			
4:00	Building a Sustainable Academic Engine for Feeding De-Risked Assets into the Biopharma Pipeline David DiGiusto, Ph.D., Executive Director, Stem Cells and Cellular Therapeutics Operations; Founding Director, Stanford Laboratory for Cell and Gene Medicine; Senior Research Scientist, Division of Pediatric Stem Transplantation and Regenerative Medicine, Stanford Health Care/ Stanford School of Medicine			
4:30	Grand Opening Reception in the Exposition Hall: "Celebration of Science" <i>co-sponsored by</i>  <i>and</i> KNect 365 <i>and</i> Lonza			
6:30	2016 BioProcess International Awards Gala Dinner and Ceremony			

WED, OCT. 5 | 4:30 pm - 6:30 pm



RECEPTION IN THE EXPOSITION HALL

Kick off your conference experience at the Opening Night Party to celebrate the launch of Biotech Week Boston! Explore our "Celebration of Science" theme with a taste of molecular gastronomy from Boston's celebrity chefs. The party will feature "Dueling DJ's", from the theater zone while you catch up with colleagues and friends, network with attendees, exhibitors and sponsors. Participate in several interactive activities and/or relax in one of the themed lounge areas. Enjoy a fun evening with food, drinks and entertainment.

Cell Therapy Bioprocessing		Tools & Technologies		Commercialization	
7:30	Coffee				
8:10	Chairperson's Remarks Jon A. Rowley, Ph.D., Chief Executive and Technical Officer, RoosterBio Inc.			Chairperson's Remarks Dominic M. Clarke, Ph.D., Global Product Manager, Cell Therapy & Bioprocessing, Charter Medical, Ltd.	
	Progress of Bioprinting & Tissue Engineering Technologies in the Clinic			Raw Materials & Supply Chain – Improving Quality, Control & Logistics Hosted by: CharterMedical	
8:15	3D Bioprinting of Vascularized Human Tissues David B. Kolesky, Ph.D., Postdoctoral Fellow, Harvard Paulson School of Engineering and Applied Sciences & The Wyss Institute for Biological Engineering			Alignment of Raw Material Qualification and Control Parameters to meet Risk-Based Assessment - It's the Details that Matter Patricia Benson, Director, Quality Operations SAFC-US, Quality, MilliporeSigma, a business of Merck KGaA, Germany	
8:45	Current Development and Clinical Perspectives of Bioprinting Technology James J. Yoo, Ph.D., MD, Professor, Institute for Regenerative Medicine, Wake Forest School of Medicine			Container Closure Integrity of Stoppered Plastic Crystal Zenith Vials Stored at Cold and Cryogenic Temperatures Eugene Polini, Market Manager, Innovation & Technology, West Pharmaceutical Services	
	Keynote Presentation				
9:30	 Harnessing Science, Technology and Innovation to Improve Global Health Toni Hoover, Ph.D., Director, Strategy, Planning, and Management for Global Health, Bill & Melinda Gates Foundation				
10:15	Networking Refreshment Break in the Exposition Hall Co-Sponsored by 				
Cell Therapy Bioprocessing		Tools & Technologies	Immuno-Oncology	Commercialization	
	Ensuring Successful Scale Up and Technology Transfers	Industrialization of Cell & Gene Therapies		Clinical Trial Design, Development & Lessons Learned	
10:30	Scale-Up of an Allogeneic Cell Therapy Product Ravi Bhatia, MSc., Scientific Director, PDMS, Janssen R&D	Ensuring Predictive not Reactive Manufacturing through Inferential Control Strategies Damian Marshall, Ph.D., Head of Analytical Development, Non-Clinical Operations, Cell & Gene Therapy Catapult, United Kingdom		Important Considerations when Planning to Treat a Neurologic Disease with Cell-Based Therapies Evan Y. Snyder, MD, Ph.D., F.A.A.P., Professor/Director, Center for Stem Cells & Regenerative Medicine, Sanford-Burnham Prebys Medical Discovery Institute, University of California, San Diego	
11:00	A New Paradigm of Scalable Manufacturing for Cell Therapy Products Daniel Giroux, Vice-President, Research and Development, PBS Biotech, Inc.	Developing Closed Processing for Viral Vector Manufacture Peter Jones, Head, Manufacturing Development, Oxford BioMedica, United Kingdom		HP802 - A Lesson for Cell Therapy Nasreen Jacobson, Ph.D., Senior Director, Research and Development, Smith & Nephew	
11:30	Ensuring Successful Technology Transfers Janet Downie, CEO, GMP Production, Roslin Cell Therapies Limited, Scotland	Enabling the Cell Therapy Factory of the Future Brian S. Hampson, MSc. Vice President, Global Manufacturing Sciences & Technology, PCT, A Caladrius Company		Presentation Title TBD Trupti Trivedi, Vice President, Biometrics, Adaptimmune, LLC	
	Technology Workshop				
12:00	Precious Cargo: Monitoring New Parameters with Today's Smart Shippers and Potential Impact on Your Therapy Heidi S. Crawford, MBA, Software Product Manager, Biologistex, BioLife Solutions, Inc.			 	
12:45	Networking Luncheon in Exposition Hall				

	Cell Therapy Bioprocessing	Tools & Technologies	Immuno-Oncology	Commercialization
2:25	Chairperson's Remarks Christopher A. Bravery, Ph.D., Consulting Regulatory Scientist, Consulting on Advanced Biologics Ltd.	Chairperson's Remarks Kim Bure, MChem, Director, Regenerative Medicine, Sartorius Stedim Biotech		Chairperson's Remarks
	Evolving Expectations & Considerations for Characterization & Comparability	Overcoming Bottlenecks and Designing Universal Development & Manufacturing Solutions		Strategies for Clinical & Commercial Launch
2:30	Characterization - from Shakespeare to Cell Therapy Anthony Davies, President, Dark Horse Consulting	Lentiviral Vector Manufacturing Strategy to Supply the Market - Scale Up Considerations James E. Miskin, Ph.D., Chief Technical Officer, Oxford Biomedica, United Kingdom		Clinical and Commercial Applications for a Platform Cell and Gene Therapy Autologous Fibroblast Program CASE STUDY John Maslowski, M.S., Senior Vice President, Scientific Affairs, Fibrocell
3:00	Identifying Stability-Indicating Parameters for Stability Studies and Beyond Christopher A. Bravery, Ph.D., Consulting Regulatory Scientist, Consulting on Advanced Biologics Ltd.	Considerations for the Design and Deployment of End to End Solutions in Cell, Gene, and Immunotherapy Manufacturing NEW DATA Kim Nguyen, Ph.D., Senior Scientist, Cell Processing, Terumo BCT		Strategies for Clinical & Commercial Launch NEW DATA David A. Brindley, MEng, DPhil, FRI, FRSA, Chief Scientific Officer, Aegate; Managing Partner, IP Asset Ventures; Senior Research Fellow, Paediatrics, University of Oxford, <i>United Kingdom</i>
3:30	iPSC Cell Based Therapy: Issues in Manufacturing NEW DATA Mahendra Rao, Vice President, Regenerative Medicine, Q Therapeutic and NYSCF	Platform Solutions for Cell Therapy Manufacturing CASE STUDY NEW DATA Eytan Abraham, Ph.D., Head, Immerging Technologies, Research and Technology, Lonza		Cord Blood-derived Allogeneic Stem Cell Therapy Product Commercialization Strategy from Korea and Beyond Antonio S. J. Lee, Ph.D., CEO & Managing Director, Medipost America Inc.
4:00	Networking Refreshment Break in the Exposition Hall Co-Sponsored by 			
	STAT Panel Discussion			
5:00	Health and the Election: The Implications of Promises and Policy on Pricing and other Issues that Matter <i>Moderator:</i> Rick Berke, Executive Editor, STAT (STATnews.com)			
6:15	Party in the Park			



PARTY IN THE PARK

Close out the last night with a bang at Party In the Park. Come and party at a first-of-its-kind outdoor interactive space in Boston, The Lawn on D.

This unique outdoor interactive experience will be filled with Bocce courts, ping-pong tables, cornhole, KanJam games. Party In the Park will feature a Main Stage under the tent with "awesome" soon to be announced entertainment.


There will be great food and drinks, food trucks, interactive activities (did someone say photo booths?) for everyone. These are the reasons why Party In the Park promises to be a night to remember!

Beer Garden Sponsor:  JSR Life Sciences

This event is free for all attendees, but an advance RSVP is required to reserve your spot. Please select the "Party In the Park" option when you register for the conference.

	Cell Therapy Bioprocessing	Tools & Technologies	Regulatory Considerations	Commercialization
7:30	Coffee			
8:00	Chairperson's Remarks		Chairperson's Remarks	Chairperson's Remarks
	Innovations in Process Technologies <i>Sponsored by:</i>  FRESENIUS KABI caring for life		International Regulatory Perspectives	Reimbursement, Pricing & Adoption
8:05	Applications for Use of the Lovo Cell Processing System in Cell Therapy NEW DATA Process Development and Manufacturing Alaina C. Schlinker, Ph.D., Senior Application Specialist, Cell Therapy, Fresenius Kabi USA, LLC		Development and Regulation of ATMPs in Europe Asterios S. Tsiftoglou, Ph.D., Professor of Pharmacology, Pharmaceutical Sciences, Aristotle University of Thessaloniki, Greece	Wilkins Micawber and the Pharmacoeconomics of Advanced Therapy Medicinal Products Anthony Davies, President, Dark Horse Consulting
8:35	Industrialization of Adenoviral Vector Production in an Icellis® 500 Fixed Bed Bioreactor for the Creation of Autologous Insulin Producing Liver Cells for the Treatment of Diabetes: From Bench to Clinical Scale Rachel Legmann, Ph.D., Manager of Cell Culture Process Development Lab and Application Specialist, Pall Life Sciences		Clinical Trial in Japan Under the New Regulatory Framework Lee Buckler, President & CEO, RepliCel	The Underpinnings of Gene Therapy Pricing Globally Aura Mackenzie, Senior Principal, Pricing & Market Access, ICON plc
9:15	Keynote Presentation			
9:15			Innovation & Customer Centricity Steve Wozniak, Co-founder, Apple Computer Inc.	
10:15	Networking Refreshment Break in the Exposition Hall Co-Sponsored by  sartorius stedim biotech			
	Innovations in Process Technologies <i>(continued)</i>		Analysis and Breakthrough Designations for Cell & Gene Therapies	Reimbursement, Pricing & Adoption <i>(continued)</i>
11:00	Platform Processes for PSC Derived Product Manufacture NEW DATA Nick Timmins, Ph.D., Vice President, Technology, Centre for Commercialization of Regenerative Medicine		Analysis of Cell and Gene Therapies – A Regulator's Perspective FDA Representative <i>(invited)</i>	Coverage, Coding, and Payment: Commercialization Issues Related to Gene Therapy Roshawn A. Blunt, Managing Director, 1798 Consultants, Inc.
11:30	Building the 3rd Pillar of Medicine: Bioprocessing for Cell Therapies CASE STUDY NEW DATA Steve K.W. Oh, Director, Stem Cell Bioprocessing & Institute Professor, Stem Cell Group, Bioprocessing Technology Institute		Leveraging Regulatory Pathways to Accelerate Development of Cell and Gene Therapies: Breakthrough Therapy Designation Dennis Williams, PharmD, Director, Global Regulatory Affairs, Adaptimmune	Critical Need for Metrics to Define “Value and Quality” in Cell Therapy Outcomes Richard T. Maziarz, M.D., Medical Director, Adult Blood and Marrow Stem Cell Transplant Program, Professor of Medicine, Oregon Health and Science University
12:00	Enabling Technologies for Efficient Downstream Processing of AAV Viral Vectors Orjana Terova, Product Manager, BioProduction - Purification, Thermo Fisher Scientific		Standards & Compliance EU Falsified Medicine Detection (FMD) and US Drug Quality and Security Act (DQSA) CASE STUDY NEW DATA David A. Brindley, MEng, DPhil, FRI, FRSA, Chief Scientific Officer, Aegate; Managing Partner, IP Asset Ventures; Senior Research Fellow, Paediatrics, University of Oxford, <i>United Kingdom</i>	Identifying & Delivering Value on the Path to Reimbursement CASE STUDY Nathan J. Dowden, MBA, Senior Vice President, Corporate Development, Rubius Therapeutics
12:30	Technology Workshop Presentations <i>(opportunities still available)</i>			
1:05	Networking Luncheon within the Exposition Hall & Last Chance to view Poster & Exhibits			

	Cell Therapy Bioprocessing	Tools & Technologies	Commercialization
2:25	Chairperson's Remarks		Chairperson's Remarks Julie Zhu, Ph.D., Associate Director, Pharmaceutical Development & Manufacturing Sciences (PDMS), Janssen Research & Development
	Innovations in Process Technologies <i>(continued)</i>		Drug Product and Fill-Finish Strategies for Cell Therapy Products
2:30	Innovative Device Development for Cell Therapies Jamie Piret, Sc.D., Professor, The University of British Columbia		Fill & Finish Operations for Cell Therapy Products: Challenges and Opportunities Maria del Pilar Redondo, Ph.D., Senior Director, Technical Operations, Tigenix, <i>Spain</i>
3:00	Applying Single-Use Technologies Paula Alves, Ph.D., CEO, iBET, <i>Portugal</i>	NEW DATA	Late Phase Fill-Finish Process Development Challenges-Case Study for A Cell Therapy Product Julie Zhu, Ph.D., Associate Director, Pharmaceutical Development & Manufacturing Sciences (PDMS), Janssen Research & Development
3:30	Manufacturing Multiple Cell Based Products Simultaneously Gail K. Naughton, Ph.D., Chairman and CEO, Histogen Inc.	CASE STUDY	Scale-up and Production Challenges in Cell Therapy Filling Brian Murphy, Ph.D., Director of Bioprocess Development, Celgene Cellular Therapeutics
4:00	Scale Out iPSC Derivation and Differentiation Processes for Cell Therapy Wen Bo Wang, Ph.D., Vice President, Process Sciences, Cellular Dynamics International, a FujiFilm company	NEW DATA	Cell Therapy Fill & Finish: New Challenges and Possible Innovative Solutions Ohad Karnieli, Ph.D., Co-founder & Chief Technology Officer, Karnieli Ltd, <i>Israel</i>
4:30	Close of Conference		



"This is a great event to keep abreast of the manufacturing advancements for the rapidly evolving cell and gene therapy industry."

– Brian Hampson, PCT, A Caladrius Company


SPONSORSHIP OPPORTUNITIES

All sponsorship opportunities can be customized to meet the individual objectives of each company. The packages may include meeting areas, branding elements, thought leadership, and customer acquisition/retention components.

THE CELL & GENE THERAPY AUDIENCE

By participating in this year’s event, you will gain unparalleled access and exposure to key decision makers.

ATTENDEES BY TITLE



GEOGRAPHY





7 Tracks





22 Content-Driven Sessions





250+ Attendees





SPONSORS

Silver Sponsor:



Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi acquired Fenwal (www.fenwalinc.com) in December 2012 and is focused on transfusion medicine, therapeutic apheresis and cellular therapy through expertise in blood collection, separation, processing, storage and transfusion. Fresenius Kabi's U.S. headquarters are located in Lake Zurich, Illinois.

Bronze Sponsors:



Session Sponsors:



Technology Workshop Sponsors:



Refreshment Break Co-Sponsor :



Networking Reception Co-Sponsors :



Exhibitors:



TO LEARN MORE AND BEGIN BUILDING YOUR CUSTOM SPONSORSHIP PACKAGE TODAY, CONTACT:

Jennifer Wickett, A-L: (508) 614-1672 • jwickett@ibcusa.com

Kristen Schott, M-Z: (508) 614-1239 • kschott@ibcusa.com

Industry Rates	Standard Rate
Main Conference (Wed-Fri)	\$2,599
Group Rates (Send 4 or more)	Standard Rate
Main Conference (Wed-Fri)	\$2,399 per person
Academic/Government Rates*	Standard Rate
Main Conference (Wed-Fri)	\$1,599 per person

*Academic/Government rates are extended to full-time employees of government, universities and university-affiliated hospitals only.



Train Your Team and Save

With 60+ speaker presentation across 3 concurrent tracks, consider sending your whole team to this year's meeting. Register a group of 4+ and receive an additional \$200 savings/person off the current industry rate. Secure your team's attendance at the lowest rate by calling Group Sales Manager Brian Schiff at bschiff@iirusa.com or 646-895-7444..



Present a Poster to Showcase Your Company's Latest Research

All poster presenters must be registered conference attendees.
The fee to present a poster in addition to your conference registration is:
Poster Fee: \$125 Academic/Government: Free
Abstract submission deadline: September 2, 2016

Conference Venue: **Boston Convention and Exhibition Center**

415 Summer St., Boston, MA 02210
Phone: 617-954-2000
web: <http://massconvention.com/about-us/contact-us/boston-convention-exhibition-center>

Hotel Accommodations:

Aloft Boston Seaport

401-403 D Street, Boston, MA 02210
Central Reservations: (877) 462-5638
Reservations Direct: (617) 530-1600
When calling Reference: Boston Biotech Week
Web link: www.starwoodmeeting.com/events/start.action?id=1601185856&key=3B2CF596

Special Room Rate:
\$349/night plus tax

Boston Park Plaza

50 Park Plaza at Arlington Street, Boston, MA 02116
Central Reservations: (800) 225-2008
Reservations Direct: (617)-426-2000
When calling Reference Code: Biotech Week
Web link: bostonparkplaza.reztrip.com/rt/ext/promoRate?property=100&mode=b&pm=true&sr=128406&vr=3

Special Room Rate:
\$329/night plus tax

Omni Parker House

60 School Street
Boston, MA 02108
Central Reservations: (800) 843-6664
Reservations Direct: (617) 227-8600
When calling Reference Code: Biotech Week
Web link: www.omnihotels.com/hotels/boston-parker-house/meetings/biotech-week-boston

Special Room Rate:
\$319/night plus tax

For full details regarding cancellation and substitution policies, visit cellgeneevent.com